OAM
MRKR icon

Oxford Asset Management’s Marker Therapeutics MRKR Stock Holding History

Oxford Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,955
Closed -$85K – 867
2019
Q4 		$85K Buy
+2,955
New +$108K ﹤0.01% 1629
2019
Q1 		– Sell
-5,060
Closed -$281K – 1859
2018
Q4 		$281K Buy
+5,060
New +$369K 0.01% 1425

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VWM
Vigilare Wealth Management Scottsdale, Arizona $326M AUM 21.58% 1-Year Est. Return

Oxford Asset Management's MRKR Position: Q1 2020 in Review

Oxford Asset Management sold out of Marker Therapeutics (MRKR) in Q1 2020, closing a stake of 2,955 shares — an estimated $85K sold.

Oxford Asset Management first reported a position in MRKR in Q4 2018 and held it in 2 quarters. The position peaked at $281K in Q4 2018. 65 funds tracked by Wall St. Rank hold MRKR as of Q1 2020.

  • Oxford Asset Management reported no remaining Marker Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 2,955 Marker Therapeutics shares in Q1 2020, an estimated $85K.
  • Oxford Asset Management first reported a position in Marker Therapeutics in Q4 2018 and held it in 2 quarters.
  • Oxford Asset Management's Marker Therapeutics position peaked at $281K in Q4 2018.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.